Markets:

Overview

News

Currencies

International

Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

7.070 -0.190 (-2.62%)

Delayed Quote Updated: 9:30 AM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

5 Analysts Have This to Say About Regenxbio ↗

June 20, 2023

Via Benzinga

RegenXbio's Potential Blockbuster: Analyst is Bullish On Stock Citing Potential Gains From AAV Gene Therapies Resurgence ↗

June 20, 2023

Baird has initiated coverage on RegenXbio Inc (NASDAQ: RGNX) with an Outperform rating and a

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 20, 2023 ↗

June 20, 2023

Via Benzinga

The Latest Analyst Ratings for Regenxbio ↗

June 02, 2023

Via Benzinga

Regenxbio's Return On Capital Employed Insights ↗

May 11, 2023

Via Benzinga

Analyst Expectations for Regenxbio's Future ↗

May 09, 2023

Via Benzinga

Earnings Preview: Regenxbio ↗

February 27, 2023

Via Benzinga

Looking Into Regenxbio's Return On Capital Employed ↗

November 22, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023 ↗

June 02, 2023

Via Benzinga

Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 16, 2023

Gainers GD Culture Group Limited (NASDAQ: GDC) shares climbed 121.9% to $9.63 after gaining over 8% on Monday. GD Culture recently announced an $11.55 million registered direct offering.

Via Benzinga

5 Analysts Have This to Say About Regenxbio ↗

November 21, 2022

Via Benzinga

What 5 Analyst Ratings Have To Say About Regenxbio ↗

November 04, 2022

Within the last quarter, Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings:

Via Benzinga

Does an FDA Fast Track Designation Make Regenxbio Stock a Buy Now? ↗

April 15, 2023

The company focuses on using its technology for gene-editing therapies.

Via The Motley Fool

Tesla To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Monday ↗

March 06, 2023

Citigroup raised the price target for The Manitowoc Company, Inc. (NYSE: MTW) from $11 to $21. Citigroup analyst Timothy Thein maintained a Neutral rating. Manitowoc shares fell 2.4% to $19.09 in...

Via Benzinga

3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday ↗

March 01, 2023

U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Regenxbio's Earnings Outlook ↗

November 02, 2022

Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Regenxbio will...

Via Benzinga

Despite Solid Efficacy From Gene Therapy, This Analyst Cuts REGENXBIO's Price Target ↗

October 04, 2022

Via Benzinga

What 4 Analyst Ratings Have To Say About Regenxbio ↗

September 09, 2022

Within the last quarter, Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings:

Via Benzinga

4 Analysts Have This to Say About Regenxbio ↗

August 10, 2022

Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings within the last quarter:

Via Benzinga

Earnings Scheduled For February 28, 2023 ↗

February 28, 2023

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.

Via Benzinga

Regenxbio Says Diabetic Retinopathy Gene Therapy Shows Meaningful Improvements In Disease Severity ↗

November 03, 2022

Via Benzinga

Recap: Regenxbio Q3 Earnings ↗

November 03, 2022

Regenxbio (NASDAQ:RGNX) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:05 AM. Here's what investors need to know about the announcement.

Via Benzinga

Expert Ratings for Regenxbio ↗

June 23, 2022

Analysts have provided the following ratings for Regenxbio (NASDAQ:RGNX) within the last quarter:

Via Benzinga

One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID

November 17, 2022

Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body....

Via FinancialNewsMedia

Alphabet To $114? Plus This Analyst Predicts $145 For Disney ↗

October 04, 2022

B of A Securities cut Alphabet Inc. (NASDAQ: GOOGL) price target from $125 to $114. Alphabet shares rose 1.9% to $100.50 in pre-market trading.

Via Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗

August 03, 2022

Via Benzinga

Earnings Scheduled For November 3, 2022 ↗

November 03, 2022

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.

Via Benzinga

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Regenxbio's Earnings Outlook ↗

August 02, 2022

Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that Regenxbio will...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022 ↗

June 23, 2022

Upgrades

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.